Autosomal dominant polycystic kidney disease (ADPKD), commonly known as polycystic kidney, is the most common genetic disorder causing renal failure in adults, with an incidence of between 1 in 500 and 1 in 4000. risk. Polycystic kidney is a congenital genetic disorder, and there is no cure for this type of disease. All current treatments for polycystic kidney revolve around reducing intracapsular pressure in the kidney cysts and reducing the workload of the surviving residual kidney units, with the aim of reducing the risk of progression to uremia. Recent guidelines for the management of autosomal dominant polycystic kidney disease (ADPKD) have been developed by Kidney Health Australia and the Kidney Disease Association of Australia and New Zealand. The guidelines were developed to help medical practitioners and patients with kidney disease to analyze the disease objectively, standardize treatment and prevent uremia. The guidelines for the diagnosis and treatment of polycystic kidney are as follows: 1. The development of polycystic kidney In the first 30 years, the symptoms of ADPKD were quite insidious. Despite the obvious cystic kidney developmental abnormalities, partly due to glomerular hyperfiltration and thus mistakenly believed that kidney function was still normal and undamaged. However, once renal function declines, irreversible damage has already occurred. Therefore, it is important to identify polycystic kidney early so that treatment measures such as strict blood pressure control can be taken to reduce the incidence of cardiovascular disease. The guidelines recommend regular glomerular filtration rate (eGFR) and urine albumin quantification to monitor renal function, and do not recommend imaging such as ultrasound or CT of the kidney to determine changes in disease unless there are other clinical reasons to repeat these tests (e.g., hematuria, pain, fever). The guidelines call for strict control of sodium intake in patients with polycystic kidney should be kept at 100mmol/day (or 2.3g of sodium per day or 6g of salt per day) or less, and appropriate control of protein intake, with a recommended dietary protein intake of (0.75-1.0g/kg/d) and no special restrictions on water intake. The aim of pharmacological treatment is to reduce overall mortality, reduce the rate of cardiovascular events, control hypertension and reduce the incidence of uremia. To this end, the guidelines recommend the routine use of antihypertensive drugs to make the target blood pressure value ≤130/80mmHg; and active lipid-lowering therapy to keep the lipid metabolism stable at the same time. 2, common treatment for polycystic kidney Reduce intrarenal pressure: angiotensin-converting enzyme inhibitor (ACEI) agents as well as their receptor antagonists (ARB) can effectively lower intra-glomerular hypertension while lowering systemic blood pressure, which is beneficial to protect cardiac and renal functions. In patients with early renal disease (eGFR > 60 ml/min/1.73 m2), BP can be lowered to 96/60-110/75 mmHg instead of the higher target of 120/70-130/80 mmHg, and lowering BP to this target slows the rate of renal enlargement accompanied by total kidney volume (TKV) expansion and also reduces the risk of cardiac enlargement. risk. The guidelines also consider the recent introduction of vasopressin receptor antagonists as perhaps the most important achievement in the pharmacological treatment of ADPKD, with studies showing that these drugs slow the growth rate of renal cysts, slow the rate of decline in renal function, and reduce chronic pain.